The Shareholders’ Committee of Boehringer Ingelheim have announced the following appointments in the Shareholders’ Committee and the Board of Managing Directors: Christian Boehringer, Chairman of the Shareholders’ Committee since 2007, has decided to step down from his position as of June 30, 2025. The Shareholders’ Committee has appointed Hubertus von Baumbach, currently Chairman of the Board of Directors, as his successor from July 1, 2025.
Shashank Deshpande, member of the Board of Managing Directors, has been appointed Chairman of the Board of Managing Directors, a responsibility that he will take on in addition to his current role leading the Human Pharma Business Unit. He will take over the Chairman’s mandate from Hubertus von Baumbach per July 1, 2025.
Shashank Deshpande joined Boehringer Ingelheim in 2012, following a decade in pharma in the US. He took on various human pharma leadership positions in Germany and Japan, ultimately as Country Managing Director Japan. In 2023, Deshpande joined the Board of Managing Directors, with responsibility for Animal Health. In 2024, he was given responsibility for Human Pharma. Shashank Deshpande holds a Master’s degree in Business Administration from the University of Hamburg, Germany.
“I am thankful that the shareholders entrust me with the Chairman’s role on the Board,” said Shashank Deshpande. “I want to acknowledge Hubertus’ leadership of the company these past nine years. You’ve built a great team, and it’s a true pleasure to be part of it. We are fully focused on bringing our strong pipeline to the market as fast as possible, and I am highly motivated to lead our organization to achieve this for the benefit of the patients and animals we serve.”
Hubertus von Baumbach was a member of the company management for 16 years, including nine years as Chairman. He added: “I wish Shashank much success; with his many years of industry experience in the US, Japan, and Germany, he will lead Boehringer through the next growth phase towards 2035.”
Source: chemanager-online.com
According to a study conducted by the company that included more than 600 participants, samples collected with the Teal Wand were shown to be just as accurate as those taken by a clinician during an office visit. About 94% of participants said they would opt for self-collection in the future, and 86% said they felt they would be more likely to stay up to date with cervical cancer screening if they could do it at home.
Jeremy Walsh was named head of IT and AI, according to his post on LinkedIn. The move was first reported by Politico. Walsh previously held the role of chief technologist at Booz Allen Hamilton, managing AI- and cloud-based projects for 14 years at the consultancy.
The new organization features two Business Groups that will rely on dedicated teams and assets to fully focus on meeting customer and market needs. Isabelle Bouvier is appointed as CEO of the Health & Pharma Solutions Business Group and Pascal Leroy as CEO of the Nutrition & Bioindustry Business Group. Béatrice Totel replaces Isabelle Bouvier as CFO of Roquette.
